The natural killer–activating receptor, <scp>NKG</scp>2<scp>D</scp>, on <scp>CD</scp>3+<scp>CD</scp>8+ <scp>T</scp> cells plays a critical role in identifying and killing autologous myeloma cells

Abstract

Clinical trials are ongoing to determine a correlation with the number and function of NKG2D+CD3+CD8+ T cells and clinical outcomes in transplanted myeloma patients, including lymphocyte recovery following transplant and overall survival.